Commonwealth Equity Services, LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Commonwealth Equity Services, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$144.95 - $152.29 $37,542 - $39,443	-259 Reduced 4.49%	5,512 $833,000
Q2 2022 Jul 19, 2022	SELL	$83.14 - $145.99 $40,073 - $70,367	-482 Reduced 7.71%	5,771 $840,000
Q1 2022 May 04, 2022	BUY	$110.08 - $142.92 $43,701 - $56,739	397 Added 6.78%	6,253 $741,000
Q4 2021 Jan 31, 2022	BUY	$99.73 - $148.48 $98,632 - $146,846	989 Added 20.32%	5,856 $807,000
Q3 2021 Oct 29, 2021	SELL	$98.85 - $138.91 $13,147 - $18,475	-133 Reduced 2.66%	4,867 $676,000
Q2 2021 Aug 11, 2021	BUY	$65.78 - $105.02 $37,757 - $60,281	574 Added 12.97%	5,000 $485,000
Q1 2021 May 04, 2021	SELL	$64.07 - $91.75 $2,306 - $3,303	-36 Reduced 0.81%	4,426 $302,000
Q4 2020 Feb 11, 2021	SELL	$65.07 - $98.24 $15,942 - $24,068	-245 Reduced 5.21%	4,462 $382,000
Q3 2020 Nov 05, 2020	BUY	$59.04 - $77.95 $11,099 - $14,654	188 Added 4.16%	4,707 $306,000
Q2 2020 Aug 12, 2020	BUY	$29.01 - $74.23 $131,096 - $335,445	4,519 New	4,519 $330,000

792K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.18B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.